Skip to content

Alumis

US · ALMS #3337 by market cap Listed 2024
6.77 -0.16 -2.31%
Live - 5344 symbols - heartbeat 160s ago · 2026-10-08 09:18
Pre-market 6.88 +1.62%
After-hours 6.77 0.00%
Overnight 6.72 -0.74%
Market cap
876.28M
P/B
1.94
EPS
-2.86
Reader sentiment Are you bullish or bearish on ALMS?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 1.94 In line with history 62nd percentile
5-year average 2.64 · #211 of 513 in Biotechnology
P/E ratio -1.65 Expensive vs history 73rd percentile
5-year average -4.62 · forward -2.19
P/S ratio 118.45 Expensive vs history 69th percentile
5-year average 84.02 · forward 200.16 · #291 of 387 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Alumis (ALMS) 876.28M -1.65 1.94 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value5.10 Economic moatNone UncertaintyExtreme

Trading 24.7% above Morningstar's fair value estimate.

Fair value

Alumis Inc receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 33% premium over our quantitative fair value estimate of $5.10 per share; however, this estimate should be taken with a pinch of salt due to its extreme uncertainty rating.

The firm's lack of profitability weakens our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's sales yield of 0.9% ranks in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are expensive.

On a different note, the firm's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 6.7, for example, ranks in the top 10% compared with peers globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 09:18:15 · For reference only, not investment advice and not tailored to your situation.